计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 ( ABCB1 )-mediated multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1.
In Vitro
TTT-28 (0-100 μM; 72 hours) reverses ABCB1-mediated MDR in drug selected SW620/Ad300 cells and transfected HEK293/ABCB1 cells; the IC 50 s of TTT-28 in CCD-18Co, SW620 and SW620/Ad300 cells are 213.4±11.0 μM, 89.4±3.9 μM and 92.0±5.0 μM, respectively. TTT-28 (10 μM; 2 hours) raises the ABCB1-mediated MDR and increased the accumulation of [ 3 H]-paclitaxel in ABCB1 overexpressing cells. TTT-28 (10 μM; 0-72 hours) does not interfer with the expression level and localization of ABCB1, it results from blocking the efflux function of ABCB1. TTT-28 (0-40 μM; 2 hours) interacts at the drug-substrate-binding site and actives the ATPase activity of ABCB1 in a concentration-dependent fashion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SW620 cells, SW620/Ad300 cells Concentration: 0.1 μM, 1 μM, 10 μM, 100 μM Incubation Time: 72 hours Result: Decreased the resistance fold of ABCB1 substrates (Paclitaxel, Doxorubicin, Vincristine) in SW620/Ad300 cells compared to SW620 cells.
In Vivo
TTT-28 (deliver orally; 30 mg/kg; every 3 rd day; 18 days) potentiates the anticancer activity of paclitaxel due to its inhibitory effect on the efflux function of ABCB1, it enhances the inhibitory effect of paclitaxel on the growth of SW620/Ad300 tumor and promoted apoptosis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5-10 week Male athymic NCR (nu/nu) nude mice ABCB1 overexpressing tumor xenograft model with SW620/Ad300 cells Dosage: 30 mg/kg Administration: Deliver orally; every 3rd day; 18 days Result: Lead to higher intratumoral accumulation of paclitaxel in tumors.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 二苯甲酮 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 二苯甲酮 |
| 其他上位类(Alternative Parents) | 芳香族苯胺 芳基苯基酮 二苯甲烷 苯甲酰胺类 苯氧基化合物 甲氧基苯 2-杂芳基酰胺 苯甲酰衍生物 茴香醚 噻唑酰胺类 2,4-二取代噻唑 烷基芳基醚 杂芳族化合物 乙烯基酰胺 仲羧酸酰胺 氮杂环化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 2-异芳基甲酰胺 - 2,4-二取代-1,3-噻唑 - 芳基醚 - 茴香醚 - 芳香族苯胺 - 芳香族杂单环化合物 - 芳基溴化物 - 芳基苯基酮 - 氮杂环 - 吡唑 - 苯甲酰胺 - 苯甲酸或衍生物 - 苯甲酮 - 苯甲酰 - 羧酰胺基 - 羧酸衍生物 - 二苯基甲烷 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 酮 - 甲氧基苯 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 苯酚醚 - 苯氧基化合物 - 醛基 - 噻唑 - 噻唑甲酰胺 - 噻唑羧酸或其衍生物 - 乙烯酰胺 |
| 描述(Description) | 该化合物属于苯甲酮类有机化合物。这类化合物含有一个与两个苯基相连的酮基团。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|